Schedule to Indemnification Agreement (March 16th, 2011)
The following is a list of the current and former directors and executive officers of Agenus who are party to an Indemnification Agreement, the form of which was filed as Exhibit 10.4 to our registration statement on Form S-1 (File No. 333-91747):
Manufacturing Technology Transfer and Supply Agreement by and Between Antigenics, Inc., a Massachusetts Corporation and Glaxosmithkline Biologicals Sa (August 9th, 2006)
License Agreement by and Between Antigenics, Inc., a Massachusetts Corporation and Glaxosmithkline Biologicals Sa (August 9th, 2006)
A number of pharmaceutical and biotechnology companies have licensed QS-21, including GlaxoSmithKline, Elan Corporation, Wyeth, Pharmexa A/S and Advanced BioScience Laboratories, Inc.
Sublease (March 15th, 2006)
This SUBLEASE is made as of February 2nd, 2006, by and between Antigenics, Inc., a Delaware corporation having an address at 630 Fifth Avenue, New York, New York 10111 (Sublessor) and Omrix Biopharmaceuticals Inc., a Delaware corporation having an address at 708 Third Avenue, New York, New York 10017 (Sublessee).
Contract (December 7th, 2005)
EXHIBIT 10.2 FIRST AMENDMENT FIRST AMENDMENT TO THE AGREEMENT made and entered into in New York, New York, by and between Antigenics, Inc. (the "Company"), a Delaware corporation with a principal place of business at 630 Fifth Ave. Suite 2100 New York, NY, and Peter Thornton of New York, New York (the "Executive"), effective as of the 21st day of June, 2004 (the "Agreement"). WHEREAS, the Company and the Executive entered into the Agreement to establish the terms and conditions of the Executive's employment with the Antigenics; and WHEREAS, the Company and the Executive now wish to amend the Agreement to modify certain material terms of their agreement to preserve their intent while reducing the risk of such terms causing the Executive to be required to include amounts in income under Section 409A of the Internal Revenue Code; NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, t
Contract (March 31st, 2005)
Exhibit 10.28 February 10, 2005 Leonard P. Paplauskas Associate Vice President for Research Administration University of Connecticut Health Center Center for Science and Technology Commercialization 263 Farmington Avenue Farmington, CT 06030 RE: ADDITIONAL COSTS APPROVED UNDER RESEARCH AGREEMENT Dear Mr. Paplauskas: This letter is in reference to that certain Research Agreement by and between University of Connecticut Health Center ("UCHC") and Antigenics Inc., a Delaware corporation ("Antigenics Inc.")(each a "Party" and collectively the "Parties") dated February 28, 1998 ("Agreement"), as amended by Amendment No. 1 Research Agreement dated April 19, 2002, further amended by Amendment Agreement dated March 18, 2003, and further amended by Amendment No. 2 to Research Agreement dated December 30, 2003 (each singly an "Amendment", collectively the "Agreement"). In accordance with the provisions of Section 5.0 of the Agreement, Antigenics Inc. hereby agrees to pay UCHC an additi
2005 Cash Compensation (December 15th, 2004)
Contract (August 9th, 2004)
CONFIDENTIAL Exhibit 10.1 This Agreement is dated June 21, 2004 and is made between Antigenics Therapeutics Limited having its registered offices at 25/28 North Wall Quay, Dublin 1 Registered No. 381308 ("The Company") and Peter Thornton of Dublin, Ireland ("Chief Financial Officer") IT IS HEREBY AGREED as follows: 1. EMPLOYMENT The Chief Financial Officer shall be employed by the Company under a Fixed Term Contract, and such employment shall be upon the terms and subject to the conditions hereinafter appearing. 2. DUTIES AND RESPONSIBILITIES 2.1. The Chief Financial Officer is hereby being employed to serve the Company as its Sr. Vice President and Chief Financial Officer, and shall perform the duties and be entitled to exercise the powers with respect to the Company, which are from time to time assigned to him or vested in him, whether or not such duties shall b